Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpoAid: Epoetin Alfa and Iron Derisomaltose for Anemia in Sepsis
NCT06670963Phase 4Recruiting
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of epoetin alfa and ferric derisomaltose in anemia (2 arms). Primary endpoint: Hemoglobin concentration difference at exit from the study. Started Nov 2024; status: recruiting.
02
Drugs
epoetin alfaferric derisomaltose
03
Conditions
anemia
Beyond the preview
Go deeper on NCT06670963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06670963.